DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor.
Zhou H, Luo Y, Lo JF, Kaplan CD, Mizutani M, Mizutani N, Lee JD, Primus FJ, Becker JC, Xiang R, et al. Proc Natl Acad Sci U S A. 2005 Aug 2; 102(31):10846-51. Epub 2005 Jul 22.